Tempus AI (NASDAQ:TEM) is a technology company specializing in the application of artificial intelligence and data science to advance precision medicine. The firm operates a cloud-based analytics platform designed to aggregate and interpret clinical and molecular data, with a particular emphasis on oncology. By leveraging machine learning algorithms, Tempus AI aims to provide healthcare professionals with actionable insights that can inform treatment decisions and improve patient outcomes.
The company’s suite of services includes comprehensive genomic profiling, digital pathology analysis and liquid biopsy testing. These services are integrated into its proprietary software platform, which allows clinicians and researchers to access standardized data sets, analytic tools and real-time reporting. Tempus AI also offers customized solutions for pharmaceutical and biotech partners, supporting drug discovery, clinical trial design and biomarker identification through advanced data modeling.
Tempus AI collaborates with a broad range of institutions, including academic medical centers, community hospitals and research organizations across North America, Europe and select markets in Asia. Its partnerships extend to pharmaceutical companies seeking to accelerate therapeutic development and to health systems aiming to streamline precision medicine workflows. The company’s global operations are supported by regional teams that focus on regulatory compliance, data governance and technical integration.
Founded in 2015 by entrepreneur Eric Lefkofsky, Tempus AI has grown from a Chicago-based start-up into a prominent player in healthcare technology. Lefkofsky serves as Chief Executive Officer, guiding strategic initiatives and fostering collaborations with industry and academic leaders. Under his leadership, the company has expanded its product offerings and invested in research partnerships to refine its AI models and broaden the application of precision oncology and other disease areas.
